Case Update 2020: Janssen Pharmaceutical Companies has changed their labels for Elmiron in the face of increasing lawsuits. Under the “Warnings” section, the United States had no risks previously listed. The new warning now includes “ Pigment changes in the retina of the eye (also referred to as pigmentary maculopathy in medical journal articles) have been reported with long-term use of ELMIRON”. The label change was recently approved by the FDA on June 16, 2020.
According to recent studies, using the drug Elmiron long-term has caused maculopathy, a disorder of the eye that can lead to blindness. Doctors who have studied Elmiron said that they had identified several patients who had developed pigmentary maculopathy after taking the medication. A report from The American Academy of Ophthalmology said that doctors who have studied the drug strongly recommend that their patients undergo eye imaging while they’re on Elmiron to see if maculopathy is present. If it is, they should stop taking the drug immediately. Patients who took Elmiron are suing the drug manufacturer, Janssen Pharmaceuticals. Patients accuse the company of not warning them about the potential dangers associated with the medication, including the risk of blindness and maculopathy.
Any patient who took Elmiron and suffered dangerous side effects will need a drug injury law firm to assist them with their case. Broughton Partners can connect law firms to Elmiron injury victims. We are a legal marketing firm that assists attorneys by helping them find qualified Elmiron plaintiffs. We deliver qualified retainers with all the files a law firm needs to work on the case. Law firms can work alongside Broughton Partners to find qualified Elmiron plaintiffs that fit the necessary case criteria.